CVS Health Corporation $CVS Shares Sold by Caisse Des Depots ET Consignations

Caisse Des Depots ET Consignations lessened its holdings in shares of CVS Health Corporation (NYSE:CVS) by 51.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 28,413 shares of the pharmacy operator’s stock after selling 30,197 shares during the quarter. Caisse Des Depots ET Consignations’ holdings in CVS Health were worth $2,142,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Concurrent Investment Advisors LLC boosted its holdings in shares of CVS Health by 20.6% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 16,193 shares of the pharmacy operator’s stock worth $1,117,000 after purchasing an additional 2,771 shares during the last quarter. Vest Financial LLC lifted its position in CVS Health by 39.3% during the second quarter. Vest Financial LLC now owns 23,268 shares of the pharmacy operator’s stock worth $1,605,000 after buying an additional 6,561 shares in the last quarter. Sequoia Financial Advisors LLC boosted its stake in CVS Health by 6.3% during the second quarter. Sequoia Financial Advisors LLC now owns 47,730 shares of the pharmacy operator’s stock worth $3,292,000 after buying an additional 2,825 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in CVS Health by 111.2% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 62,627 shares of the pharmacy operator’s stock valued at $4,320,000 after buying an additional 32,981 shares in the last quarter. Finally, Cornerstone Wealth Group LLC acquired a new stake in shares of CVS Health in the 2nd quarter worth $266,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Q4 beat and record revenue — CVS reported Q4 revenue of $105.7B (up 8.2%) and adjusted EPS that topped estimates, driven by Pharmacy and PBM strength; management cites progress on its turnaround. PR News Release
• Positive Sentiment: Analysts see multiple growth levers for 2026 — Sell‑side commentators highlight continued PBM, retail pharmacy margin recovery, and Aetna enrollment/efficiencies as upside drivers. Analysts See Multiple Growth Levers For CVS Health In 2026
• Positive Sentiment: Operational wins: cost‑based pharmacy transition & improved prior‑auth performance at Aetna — items that support margin recovery and execution credibility. PR News Release
• Neutral Sentiment: Sector context — Oscar Health and other insurers posted diverging 2025 results, keeping investor focus on insurer exposure and reimbursement trends rather than CVS‑specific fundamentals. CVS, Oscar Health report diverging 2025 results
• Neutral Sentiment: Mixed analyst commentary — some outlets and commentators (e.g., Jim Cramer) call CVS an attractive turnaround play, which supports sentiment but contrasts with caution around policy and guidance. Jim Cramer on CVS
• Negative Sentiment: Guidance shortfall vs. Street — management issued FY‑2026 EPS guidance (~$5.94–$6.14) below consensus estimates, prompting concern that near‑term earnings targets may be conservative versus sell‑side models. Zacks: Beats but Shares Slide
• Negative Sentiment: Medicare/MA rate concerns — investor worry about proposed Medicare rate changes and a “disappointing” 2027 Medicare Advantage rate notice from management weighed on sentiment and triggered earlier selling. Barron’s: Medicare Worries
• Negative Sentiment: Cash‑flow/guidance nuances — some reports flag lowered cash‑flow guidance or in‑line items that temper the upbeat revenue beat, which can pressure valuation near term. Investing.com: Cash Flow Guidance Lowered

CVS Health Price Performance

CVS opened at $76.88 on Thursday. The stock’s 50-day moving average price is $78.55 and its 200 day moving average price is $75.98. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15. The firm has a market cap of $97.59 billion, a price-to-earnings ratio of 55.71, a PEG ratio of 0.70 and a beta of 0.50. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The company had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The business’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.19 earnings per share. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, sell-side analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were paid a $0.665 dividend. The ex-dividend date was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. CVS Health’s payout ratio is 700.00%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on CVS. UBS Group reissued an “outperform” rating on shares of CVS Health in a research report on Wednesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of CVS Health in a report on Wednesday, December 10th. Jefferies Financial Group raised their price target on shares of CVS Health from $92.00 to $98.00 in a report on Thursday, October 30th. Mizuho upped their price objective on CVS Health from $88.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of CVS Health in a research report on Monday, December 29th. Nineteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.82.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.